Rigel Pharmaceuticals Total Assets 2010-2025 | RIGL

Rigel Pharmaceuticals total assets from 2010 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Rigel Pharmaceuticals Annual Total Assets
(Millions of US $)
2024 $164
2023 $117
2022 $134
2021 $167
2020 $110
2019 $148
2018 $139
2017 $119
2016 $78
2015 $132
2014 $154
2013 $226
2012 $310
2011 $257
2010 $187
2009 $141
Rigel Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2025-03-31 $176
2024-12-31 $164
2024-09-30 $139
2024-06-30 $128
2024-03-31 $127
2023-12-31 $117
2023-09-30 $115
2023-06-30 $117
2023-03-31 $124
2022-12-31 $134
2022-09-30 $116
2022-06-30 $128
2022-03-31 $149
2021-12-31 $167
2021-09-30 $187
2021-06-30 $202
2021-03-31 $216
2020-12-31 $110
2020-09-30 $123
2020-06-30 $138
2020-03-31 $143
2019-12-31 $148
2019-09-30 $156
2019-06-30 $156
2019-03-31 $173
2018-12-31 $139
2018-09-30 $123
2018-06-30 $141
2018-03-31 $99
2017-12-31 $119
2017-09-30 $71
2017-06-30 $85
2017-03-31 $101
2016-12-31 $78
2016-09-30 $89
2016-06-30 $99
2016-03-31 $108
2015-12-31 $132
2015-09-30 $139
2015-06-30 $148
2015-03-31 $166
2014-12-31 $154
2014-09-30 $163
2014-06-30 $182
2014-03-31 $203
2013-12-31 $226
2013-09-30 $240
2013-06-30 $262
2013-03-31 $283
2012-12-31 $310
2012-09-30 $194
2012-06-30 $214
2012-03-31 $234
2011-12-31 $257
2011-09-30 $276
2011-06-30 $290
2011-03-31 $166
2010-12-31 $187
2010-09-30 $201
2010-06-30 $196
2010-03-31 $217
2009-12-31 $141
2009-09-30 $164
2009-06-30 $88
2009-03-31 $114
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.343B $0.179B
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.830B 32.20
Zoetis (ZTS) United States $75.075B 28.01
Daiichi Sankyo, - (DSNKY) Japan $50.952B 25.92
Takeda Pharmaceutical (TAK) Japan $47.824B 9.51
Sandoz Group AG (SDZNY) Switzerland $22.282B 0.00
Merck (MKKGY) Germany $17.034B 12.48
United Therapeutics (UTHR) United States $14.382B 12.72
Shionogi (SGIOY) Japan $14.036B 14.06
Summit Therapeutics (SMMT) United States $13.528B 0.00
Neurocrine Biosciences (NBIX) United States $12.175B 41.70
IPSEN (IPSEY) France $9.924B 0.00
Orion OYJ (ORINY) Finland $9.462B 25.59
Corcept Therapeutics (CORT) United States $8.225B 66.86
Stevanato Group S.p.A (STVN) Italy $6.726B 41.13
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.112B 0.00
Grifols, S.A (GRFS) Spain $5.714B 0.00
Ionis Pharmaceuticals (IONS) United States $5.333B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.696B 0.00
Catalyst Pharmaceuticals (CPRX) United States $3.045B 10.67
Crinetics Pharmaceuticals (CRNX) United States $2.857B 0.00
Hypermarcas (HYPMY) Brazil $2.812B 18.50
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.294B 12.41
BioCryst Pharmaceuticals (BCRX) United States $2.249B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.033B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.804B 0.00
Indivior (INDV) United States $1.773B 7.52
Recursion Pharmaceuticals (RXRX) United States $1.699B 0.00
ARS Pharmaceuticals (SPRY) United States $1.417B 0.00
Evotec AG (EVO) Germany $1.410B 0.00
Dyne Therapeutics (DYN) United States $1.359B 0.00
Guardian Pharmacy Services (GRDN) United States $1.340B 0.00
Ocular Therapeutix (OCUL) United States $1.276B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.059B 21.19
Harrow (HROW) United States $1.031B 0.00
Collegium Pharmaceutical (COLL) United States $0.936B 5.05
Avadel Pharmaceuticals (AVDL) Ireland $0.881B 0.00
Ardelyx (ARDX) United States $0.878B 0.00
Enliven Therapeutics (ELVN) United States $0.872B 0.00
Akebia Therapeutics (AKBA) United States $0.796B 0.00
Xeris Biopharma Holdings (XERS) United States $0.773B 0.00
Cronos Group (CRON) Canada $0.763B 0.00
AleAnna (ANNA) United States $0.624B 0.00
KalVista Pharmaceuticals (KALV) United States $0.587B 0.00
Elite Pharmaceuticals (ELTP) United States $0.577B 0.00
Xencor (XNCR) United States $0.569B 0.00
USANA Health Sciences (USNA) United States $0.556B 12.09
Regulus Therapeutics (RGLS) United States $0.549B 0.00
Bioventus (BVS) United States $0.532B 13.50
Relay Therapeutics (RLAY) United States $0.514B 0.00
Zevra Therapeutics (ZVRA) United States $0.468B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.459B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.458B 0.00
Altimmune (ALT) United States $0.440B 0.00
Tourmaline Bio (TRML) United States $0.428B 0.00
Siga Technologies (SIGA) United States $0.427B 8.93
CytoDyn (CYDY) United States $0.427B 0.00
Oruka Therapeutics (ORKA) United States $0.410B 0.00
Verve Therapeutics (VERV) United States $0.397B 0.00
Savara (SVRA) United States $0.394B 0.00
Organogenesis (ORGO) United States $0.348B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.291B 0.00
Heron Therapeutics (HRTX) United States $0.287B 0.00
Nature's Sunshine Products (NATR) United States $0.284B 26.20
Aquestive Therapeutics (AQST) United States $0.269B 0.00
MediWound (MDWD) Israel $0.237B 0.00
ProKidney (PROK) United States $0.212B 0.00
Nanobiotix S.A (NBTX) France $0.193B 0.00
Journey Medical (DERM) United States $0.188B 0.00
Esperion Therapeutics (ESPR) United States $0.168B 0.00
4D Molecular Therapeutics (FDMT) United States $0.168B 0.00
Profound Medical (PROF) Canada $0.158B 0.00
Aclaris Therapeutics (ACRS) United States $0.158B 0.00
OmniAb (OABI) United States $0.155B 0.00
Inhibikase Therapeutics (IKT) United States $0.149B 0.00
Avita Medical (RCEL) United States $0.149B 0.00
Wellgistics Health (WGRX) United States $0.144B 0.00
Larimar Therapeutics (LRMR) United States $0.144B 0.00
Liminatus Pharma (LIMN) $0.141B 0.00
Nektar Therapeutics (NKTR) United States $0.135B 0.00
Lyell Immunopharma (LYEL) United States $0.129B 0.00
Aldeyra Therapeutics (ALDX) United States $0.129B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.127B 0.00
Achieve Life Sciences (ACHV) Canada $0.124B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Protara Therapeutics (TARA) United States $0.117B 0.00
Korro Bio (KRRO) United States $0.107B 0.00
Cardiol Therapeutics (CRDL) Canada $0.103B 0.00
VAXART, INC (VXRT) United States $0.099B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Cassava Sciences (SAVA) United States $0.097B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.097B 0.00
Fractyl Health (GUTS) United States $0.093B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.091B 0.00
Lexeo Therapeutics (LXEO) United States $0.090B 0.00
Inotiv (NOTV) United States $0.089B 0.00
Arch Biopartners (ACHFF) Canada $0.085B 0.00
Galectin Therapeutics (GALT) United States $0.083B 0.00
Champions Oncology (CSBR) United States $0.081B 13.34
Pyxis Oncology (PYXS) United States $0.075B 0.00
Vivani Medical (VANI) United States $0.075B 0.00
ESSA Pharma (EPIX) Canada $0.075B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.074B 55.11
Surrozen (SRZN) United States $0.073B 0.00
Nutriband (NTRB) United States $0.073B 0.00
Unicycive Therapeutics (UNCY) United States $0.071B 0.00
Dominari Holdings (DOMH) United States $0.065B 0.00
Assertio Holdings (ASRT) United States $0.064B 0.00
Metagenomi (MGX) United States $0.064B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Telomir Pharmaceuticals (TELO) United States $0.058B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Context Therapeutics (CNTX) United States $0.052B 0.00
Prelude Therapeutics (PRLD) United States $0.050B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.046B 0.00
Century Therapeutics (IPSC) United States $0.046B 0.00
NRx Pharmaceuticals (NRXP) United States $0.046B 0.00
PMV Pharmaceuticals (PMVP) United States $0.046B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.045B 0.00
Mural Oncology (MURA) Ireland $0.045B 0.00
Avalo Therapeutics (AVTX) United States $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.040B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Karyopharm Therapeutics (KPTI) United States $0.036B 0.00
Rafael Holdings (RFL) United States $0.036B 0.00
SCYNEXIS (SCYX) United States $0.034B 0.00
Acrivon Therapeutics (ACRV) United States $0.033B 0.00
FibroGen (FGEN) United States $0.029B 0.00
PolyPid (PYPD) Israel $0.029B 0.00
Jupiter Neurosciences (JUNS) United States $0.026B 0.00
Relmada Therapeutics (RLMD) United States $0.025B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
China SXT Pharmaceuticals (SXTC) China $0.022B 0.00
Tempest Therapeutics (TPST) United States $0.022B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.019B 0.00
Lipocine (LPCN) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.018B 0.00
BioLineRx (BLRX) Israel $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
DURECT (DRRX) United States $0.016B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
VYNE Therapeutics (VYNE) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Ainos (AIMD) United States $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Scienture Holdings (SCNX) United States $0.011B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Minerva Neurosciences (NERV) United States $0.011B 1.88
Talphera (TLPH) United States $0.010B 0.00
Phio Pharmaceuticals (PHIO) United States $0.010B 0.00
SHINECO (SISI) China $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Traws Pharma (TRAW) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.007B 0.00
Lyra Therapeutics (LYRA) United States $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00